Clinical Trial: IgG Binding Protein LT in Support of a Healthy Gut on the Go

U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07873957) titled 'IgG Binding Protein LT in Support of a Healthy Gut on the Go' on Oct. 06.

Brief Summary: PS52 is a randomized, double-blind, placebo-controlled, fully decentralized study sponsored by Bactolife A/S and conducted by People Science, Inc. It evaluates whether IgG Binding Protein LT (BP-LT), supports gut health in healthy US adults aged 18-70 travelling 7-21 days to Africa, Asia or Latin America/Caribbean countries. Participants are randomized 1:1 to BP-LT (one 75 mg capsule twice daily with food, 150 mg/day) or a matching placebo for the length of their trip. The primary endpoint is the change in GSRS total score from Baseline to End-o...